Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: A GAPDH nucleic acid detection kit includes a primer set for detecting GAPDH nucleic acid. The primer set for detecting GAPDH nucleic acid includes a forward inner primer for GAPDH nucleic acids, a forward outer primer for GAPDH nucleic acids, a backward inner primer for GAPDH nucleic acids and a backward outer primer for GAPDH nucleic acids. The primer set for detecting GAPDH nucleic acid is used in a loop-mediated isothermal amplification (LAMP).

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: A GAPDH nucleic acid detection kit includes a primer set for detecting GAPDH nucleic acid. The primer set for detecting GAPDH nucleic acid includes a forward inner primer for GAPDH nucleic acids, a forward outer primer for GAPDH nucleic acids, a backward inner primer for GAPDH nucleic acids and a backward outer primer for GAPDH nucleic acids. The primer set for detecting GAPDH nucleic acid is used in a loop-mediated isothermal amplification (LAMP).

Abstract: A method for screening host cells expressing a target protein is provided. The method includes the following steps: providing an expression vector, the expression vector including a promoter, a gene encoding a target protein and an FTH1 gene; transfecting the host cells with the expression vector; culturing the host cells in a medium; and adding iron ions to the medium, and screening the surviving host cells to obtain the host cells expressing the target protein. An expression vector and a method for establishing a cell line stably expressing an exogenous recombinant gene are also provided.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: A humanized monoclonal antibody against the CD34 surface antigen is provided in the present disclosure. The humanized monoclonal antibody includes a light chain variable region and a heavy chain variable region. In which, a nucleotide sequence encoding the amino acid sequence for the light chain variable region comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID No. 9 or an amino acid sequence with at least 80% sequence identity to the sequence of SEQ ID No. 9, and a nucleotide sequence encoding the amino acid sequence for the heavy chain variable region comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID No. 10 or an amino acid sequence with at least 80% sequence identity to the sequence of SEQ ID No. 10.

Abstract: The present invention relates to a method for producing multivalent Fab fragments. In particular, the invention relates to a method for the generation of trimeric Fab fragments by co-expression of a gene construct comprising a heavy chain portion of a Fab fragment and an in-frame fused collagen-like peptide, and a gene construct consisting of a light chain portion of an IgG in mammalian cells. Uses of molecules generated using the method of the invention are also described.

Abstract: A collagen scaffold domain, including a collagenous or collagen-like domain, which directs self-trimerization is provided. The collagen scaffold domain can be fused to one or more heterologous domains, such as an antibody domain. Methods for generating and using the scaffold domains and fusion proteins are also provided.

Abstract: A humanized monoclonal antibody against the CD34 surface antigen is provided in the present disclosure. The humanized monoclonal antibody includes a light chain variable region and a heavy chain variable region. In which, a nucleotide sequence encoding the amino acid sequence for the light chain variable region comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID No. 9 or an amino acid sequence with at least 80% sequence identity to the sequence of SEQ ID No. 9, and a nucleotide sequence encoding the amino acid sequence for the heavy chain variable region comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID No. 10 or an amino acid sequence with at least 80% sequence identity to the sequence of SEQ ID No. 10.

Abstract: A novel humanized antibody against the CD34 surface antigen on the human stem cells is provided. The humanized antibody contains a heavy chain variable region comprising an amino sequence as set forth in SEQ ID No. 1 and a light chain variable region comprising an amino sequence as set forth in SEQ ID No. 2. The disclosure also provides the applications of the disclosed humanized antibody.

Abstract: The present invention relates to a method for producing multivalent Fab fragments. In particular, the invention relates to a method for the generation of trimeric Fab fragments by co-expression of a gene construct comprising a heavy chain portion of a Fab fragment and an in-frame fused collagen-like peptide, and a gene construct consisting of a light chain portion of an IgG in mammalian cells. Uses of molecules generated using the method of the invention are also described.

Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.

Abstract: An amino acid sequence of a humanized monoclonal antibody includes an amino acid sequence of a light chain variable region, which includes SEQ ID. NO.: 1; and an amino acid sequence of a heavy chain variable region, which comprises SEQ ID. NO.: 2, wherein SEQ ID. NO.: 1 and SEQ ID. NO.: 2 have at least one amino acid substitution which is selected from a group consisting of isoleucine at position 10 of SEQ ID. NO.: 1, being substituted with threonine, lysine at position 18 of SEQ ID. NO.: 1, being substituted with arginine, lysine at position 2 of SEQ ID. NO.: 2, being substituted with glutamine, tryptophan at position 10 of SEQ ID. NO.: 2, being substituted with leucine, lysine at position 18 of SEQ ID. NO.: 2, being substituted with arginine and glutamic acid at position 41 of SEQ ID. NO.: 2, being substituted with glycine.

Abstract: The embodiments of the invention relate to compositions, methods, and kits comprising a fusion protein. The fusion proteins of the embodiments include monomer polypeptides which in one embodiment have at least a binding domain, an optional hinge region, a collagen-like domain and the Fc domain of a human IgG.

Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.

Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.

Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.

Abstract: The embodiments of the invention relate to compositions, methods, and kits comprising a fusion protein. The fusion proteins of the embodiments include monomer polypeptides which in one embodiment have at least a binding domain, an optional hinge region, a collagen-like domain and the Fc domain of a human IgG.

Abstract: An amino acid sequence of a humanized monoclonal antibody includes an amino acid sequence of a light chain variable region, which includes SEQ ID. NO.: 1; and an amino acid sequence of a heavy chain variable region, which comprises SEQ ID. NO.: 2, wherein SEQ ID. NO.: 1 and SEQ ID. NO.: 2 have at least one amino acid substitution which is selected from a group consisting of isoleucine at position 10 of SEQ ID. NO.: 1, being substituted with threonine, lysine at position 18 of SEQ ID. NO.: 1, being substituted with arginine, lysine at position 2 of SEQ ID. NO.: 2, being substituted with glutamine, tryptophan at position 10 of SEQ ID. NO.: 2, being substituted with leucine, lysine at position 18 of SEQ ID. NO.: 2, being substituted with arginine and glutamic acid at position 41 of SEQ ID. NO.: 2, being substituted with glycine.